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Purpose: Stem cell factor (SCF)/c-kit signaling promotes recruitment of endothelial progenitor cells and contributes to
ischemia-induced new vessel formation. We investigated the expression of the components of this pathway, including c-
kit, SCF, granulocyte colony-stimulating factor (G-CSF), endothelial nitric oxide synthase (eNOS), and the chemokine
receptor CXCR4, in proliferative diabetic retinopathy (PDR) epiretinal membranes.
Methods:  Membranes  from  eight  patients  with  active  PDR  and  12  patients  with  inactive  PDR  were  studied  by
immunohistochemistry.
Results: Blood vessels expressed c-kit, SCF, G-CSF, eNOS, and CXCR4 in 18, 15, 19, 20, and 20 out of 20 membranes,
respectively. Significant correlations were detected between the number of blood vessels expressing CD34 and the number
of blood vessels expressing SCF (r=0.463; p=0.04), G-CSF (r=0.87; p<0.001), eNOS (r=0.864; p<0.001), and CXCR4
(r=0.864; p<0.001). Stromal cells expressed c-kit, SCF, eNOS, and CXCR4 in 19, 15, 20, and 20 membranes, respectively.
The numbers of blood vessels expressing CD34 (p=0.005), c-kit (p=0.03), G-CSF (p=0.007), eNOS (p=0.001), and
CXCR4 (p=0.018) and stromal cells expressing c-kit (p=0.013), SCF (p<0.001), eNOS (p=0.048), and CXCR4 (p=0.003)
were significantly higher in active membranes than in inactive membranes.
Conclusions: SCF/c-kit signaling might contribute to neovascularization in PDR.
Ischemia-induced  retinal  neovascularization  in
association  with  the  outgrowth  of  fibrovascular  epiretinal
membranes at the vitreoretinal interface is a hallmark feature
of proliferative diabetic retinopathy (PDR) and often leads to
severe visual loss due to vitreous hemorrhage and/or tractional
retinal  detachment.  Increasing  evidence  suggests  that
circulating bone marrow-derived endothelial progenitor cells
(EPCs) home to the ischemic region, differentiate into mature
endothelial cells in situ, and can contribute to the process of
neovascularization [1].
Stem cell factor (SCF), or kit ligand, is a peptide growth
factor that exists as a membrane-bound protein but may be
cleaved  by  proteases,  such  as  matrix  metalloproteinase-9
(MMP-9),  to  produce  a  soluble  cytokine  [2,3].  SCF  is
important for the survival and differentiation of hematopoietic
stem cells. The receptor for SCF, the proto-oncogene c-kit, is
a tyrosine kinase that is expressed by bone marrow-derived
endothelial stem/progenitor cells [4,5]. SCF ligand binding
leads to phosphorylation and activation of the c-kit receptor
and  its  downstream  signaling  proteins,  which  have  been
implicated in cell proliferation, cell adhesion, and cell survival
as  well  as  chemotaxis  [3,6].  Several  studies  have
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demonstrated that SCF/c-kit signaling promotes the survival,
migration  differentiation,  and  capillary  tube  formation  of
endothelial cells [6,7] and plays an important role in ischemia-
induced neovascularization [2,4,6,8-10].
The cytokine granulocyte colony-stimulating factor (G-
CSF) has been shown to promote the mobilization of bone
marrow-derived  c-kit+  EPCs  and  to  enhance
neovascularization  of  ischemic  tissue  [11].  In  addition,
endothelial nitric oxide synthase (eNOS) is crucial for the
recruitment of EPCs in the circulation from the bone marrow
and for firm c-kit+ cell adhesion to the vascular endothelium.
eNOS  is  also  required  for  neovascularization  in  ischemic
tissue [12-15]. Researchers have also reported that c-kit+ cells
express the chemokine stromal cell-derived factor-1 (SDF-1)
receptor CXCR4 and that SDF-1 induces their migration [12,
13].
Understanding the molecular mechanisms involved in the
pathologic neovascularization observed in PDR is important
for  identifying  novel  targets  for  anti-angiogenic  therapy.
Given the role of the SCF/c-kit signaling pathway in ischemia-
induced neovascularization, we hypothesized that SCF/c-kit
signaling may play a role in PDR. The aim of the present study
was, therefore, to examine the expression of SCF, c-kit, G-
CSF,  eNOS,  and  CXCR4  in  epiretinal  membranes  from
patients with PDR. The level of vascularization in epiretinal
membranes  was  determined  by  immunodetection  of  the
panendothelial cell marker CD34.
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1098METHODS
Epiretinal  membrane  specimens:  Epiretinal  fibrovascular
membranes were obtained from 20 patients with PDR during
pars  plana  vitrectomy  for  the  repair  of  traction  retinal
detachment  or  combined  traction/  rhegmatogenous  retinal
detachment. Fourteen (70%) patients were male and 6 (30%)
were female. The age ranged from 25 to 64 years, with a mean
of  47.7±13.7  years.  Fifteen  (75%)  patients  had  insulin-
dependent diabetes mellitus, and 5 (25%) had non-insulin-
dependent diabetes mellitus. Duration of diabetes ranged from
12  to  34  years  with  a  mean  of  22.1±6.9  years.  Level  of
glycosylated hemoglobin ranged from 7.3% to 13.2% with a
mean  of  9.0±1.6%.  Using  the  operating  microscope,  the
clinical ocular findings were graded at the time of vitrectomy
for the presence or absence of visible new vessels on the retina
or optic disc. Patients with active PDR were graded as such
on the basis of visible new vessels on the retina or optic disc.
Their  absence  indicated  involuted  (inactive)  PDR.  Active
PDR was present in eight patients, and inactive PDR was
present in 12 patients. Membranes were fixed in 10% formalin
solution and embedded in paraffin. The study was conducted
according to the tenets of the Declaration of Helsinki, and
informed consent was obtained from all patients. The study
was approved by the Research Center, College of Medicine,
King Saud University, Riyadh, Saudi Arabia.
Immunohistochemical staining: Endogenous peroxidase was
abolished with 2% hydrogen peroxide in methanol for 20 min,
and  nonspecific  background  staining  was  blocked  by
incubating the sections for 5 min in normal swine serum. For
c-kit detection, antigen retrieval was performed by boiling the
sections in 10 mM EDTA buffer (pH 9.0; Sigma-Aldrich,
Bornem, Belgium) for 30 min. For CD34, SCF, G-CSF, and
eNOS detection, antigen retrieval was performed by boiling
the sections in 10 mM citrate buffer (pH 6.0) for 30 min.
Subsequently,  the  sections  were  incubated  with  the
monoclonal and polyclonal antibodies listed in Table 1. The
optimal working concentration and incubation time for the
antibodies were determined earlier in pilot experiments. For
SCF, a second step was introduced using 1/20 rabbit antigoat
peroxidase plus 1/10 normal human serum. The sections were
then incubated for 30 min with immunoglobulin conjugated
to  peroxidase-labeled  dextran  polymer  (EnVision  [Flex];
Dako, Carpinteria, CA). The reaction product was visualized
by incubation for 10 min in 0.05 M acetate buffer at pH 4.9
containing 0.05% 3-amino-9-ethylcarbazole (Sigma-Aldrich)
and  0.01%  hydrogen  peroxide,  resulting  in  bright-red
immunoreactive sites or containing 3, 3′-diaminobenzidine
(Dako)  and  hydrogen  peroxide,  resulting  in  brown
immunoreactive  sites.  The  slides  were  then  faintly
counterstained with Harris hematoxylin.
To identify the phenotype of cells expressing c-kit or
CXCR4,  sequential  double  immunohistochemistry  was
performed as previously described [16].
Omission or substitution of the primary antibody with an
irrelevant antibody of the same species and staining with
chromogen alone were used as negative controls. Sections
from patients with colorectal carcinoma were used as positive
controls. Archived paraffin-embedded tissue sections from
the control patients were obtained from patients treated at the
University Hospital, University of Leuven, Belgium, in full
compliance with tenets of the Declaration of Helsinki.
Quantitation: Immunoreactive blood vessels and cells were
counted  in  five  representative  fields,  using  an  eyepiece
calibrated grid in combination with a 40× objective. These
representative fields were selected based on the presence of
immunoreactive blood vessels and stromal cells. With this
magnification  and  calibration,  the  blood  vessels  and  cells
present in an area of 0.33×0.22 mm were counted. Data were
expressed as mean values ±standard deviation and analyzed
by the Mann–Whitney test. Pearson correlation coefficients
were computed to investigate the linear relationship between
the variables investigated. A p value less than 0.05 indicated
statistical significance. The BMDP 2007 statistical package
(BMDP Statistical Software, Inc., Los Angeles, CA) was used
for the statistical analysis.
RESULTS
Immunohistochemical analysis: No staining was observed in
the  negative  control  slides  (Figure  1A).  All  membranes
showed  blood  vessels  positive  for  the  panendothelial  cell
marker CD34, with a mean number of 28.4±17.2 (range, 7–
70). In addition, stromal cells expressing CD34 were noticed
TABLE 1. MONOCLONAL AND POLYCLONAL ANTIBODIES USED IN THIS STUDY.
Primary antibody Dilution Incubation time Source*
Anti-CD34 (Clone My 10) (mc) 1/50 60 min BD Biosciences
Anti-c- kit (Code A4502 (pc) 1/20 60 min Dako
Anti-SCF (Catalogue No. AB-255-NA) (mc) 1/10 60 min R&D Systems
Anti-G-CSF (FL-207) sc-13102 (pc) 1/200 60 min Santa Cruz Biotechnology, Inc.
Anti-eNOS (Clone 3/eNOS/NOS Type III) (mc) 1/20 60 min BD Biosciences
Anti-CXCR4 (Clone 44716) (mc) 1/100 60 min R&D Systems
*Location of manufacturers: BD Biosciences, San Jose, CA; Dako, Glostrup, Denmark; R&D Systems, Abingdon, UK; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA. Abbreviations: mc represents monoclonal ; pc represents polyclonal.
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1099in  close  association  with  blood  vessels  (Figure  1B).
Immunoreactivity  for  c-kit  was  present  in  19  (95%)
membranes. c-kit immunoreactivity was observed on vascular
endothelial cells (Figure 1C) in 18 (90%) membranes, with a
mean number of 9.1±6.7 (range, 0–25). Immunoreactivity for
c-kit was also defined in stromal cells (Figure 1D) in 19 (95%)
membranes, with a mean number of 24.6±32.1 (range, 0–140).
Immunoreactivity  for  SCF  was  present  in  15  (75%)
membranes  (Figure  2A-C).  Strong  SCF  immunoreactivity
was noticed on vascular endothelial cells (Figure 2A,B), with
a  mean  number  of  5.1±5.5  (range,  0–20).  SCF
immunoreactivity was also observed in stromal cells (Figure
2B),  with  a  mean  number  of  11.6±9.3  (range,  0–30).
Immunoreactivity  for  G-CSF  was  present  in  19  (95%)
membranes on vascular endothelial cells (Figure 2D), with a
mean  number  of  10.4±8  (range,  0–28).  There  was  no
immunoreactivity for G-CSF in stromal cells. All membranes
showed  strong  immunoreactivity  for  eNOS.
Immunoreactivity  for  eNOS  was  visualized  on  vascular
endothelial cells (Figure 2E), with a mean number of 22±10.3
(range, 4–40). Immunoreactivity for eNOS was also seen in
stromal cells (Figure 2F,G), with a mean number of 28±21.8
(range, 5–100). Strong immunoreactivity for the chemokine
receptor  CXCR4  was  present  in  all  membranes.
Immunoreactivity  for  CXCR4  was  observed  on  vascular
endothelial cells (Figure 3A) in 19 (95%) membranes, with a
mean number of 21.2±12.6 (range, 0–55). Immunoreactivity
for CXCR4 was also defined in stromal cells (Figure 3B) in
all membranes, with a mean number of 69.8±46.4 (range, 12–
150).
c-kit+, eNOS+, and CXCR4+ stromal cells were closely
associated with the new vessels within the membranes. In
serial sections, the distribution of cells expressing c-kit was
similar  to  the  distribution  of  cells  expressing  eNOS  and
CXCR4  (Figure  1D,  Figure  2F,  Figure  3B).  Double
immunohistochemistry confirmed that c-kit+ cells also co-
expressed  the  chemokine  SDF-1  receptor  CXCR4  in  the
vascular endothelium and in the stroma (Figure 3C).
Figure 1. Negative control slide that was treated identically with an irrelevant antibody. No labeling was observed (A: original magnification
40×). Immunohistochemical staining for CD34. Blood vessels and stromal cells showed immunoreactivity for CD34 (B: original magnification
40×). Immunohistochemical staining for c-kit. Vascular endothelial cells (C: original magnification 100×) and stromal cells (D: original
magnification 40×) showed immunoreactivity for c-kit.
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1100Figure  2.  Immunohistochemical  staining  for  stem  cell  factor  (SCF).  Vascular  endothelial  cells  and  stromal  cells  expressed  strong
immunoreactivity for SCF in a membrane from a patient with active proliferative diabetic retinopathy (PDR). A: Low power, original
magnification 40×. B: high-power, original magnification 100×. SCF immunoreactivity is absent in a membrane from a patient with inactive
PDR. Note that the membrane is composed mostly of fibrous tissue (C: original magnification 40×). Immunohistochemical staining for
granulocyte colony-stimulating factor (G-CSF). G-CSF immunoreactivity was observed in vascular endothelial cells (D: original magnification
100×). Immunohistochemical staining for endothelial nitric oxide synthase (eNOS). Immunoreactivity for eNOS was observed in vascular
endothelial cells (E: original magnification 100×) and stromal cells (F: Low-power, original magnification 40× and G: high-power, original
magnification 100×).
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1101Correlations  and  relationship  with  proliferative  diabetic
retinopathy  activity:  The  mean  number  of  blood  vessels
expressing  CD34,  c-kit,  G-CSF,  eNOS,  and  CXCR4  and
stromal cells expressing c-kit, SCF, eNOS, and CXCR4 were
significantly higher in membranes from patients with active
PDR than in membranes from patients with inactive PDR
(Table  2).  Table  3  shows  Pearson  correlation  coefficients
between the numbers of the studied variables.
DISCUSSION
In this immunohistochemical study of PDR membranes, the
principal  findings  are  that  (a)  PDR  membranes  showed
immunoreactivity for SCF, c-kit, G-CSF, eNOS, and CXCR4
in vascular endothelial cells; (b) stromal cells expressed SCF,
c-kit, eNOS, and CXCR4; (c) c-kit+ cells co-expressed the
chemokine receptor CXCR4 and eNOS; (d) the number of
blood vessels expressing CD34, c-kit, G-CSF, eNOS, and
CXCR4 and the number of stromal cells expressing c-kit,
SCF, eNOS, and CXCR4 in membranes from patients with
active PDR were significantly higher than those in membranes
from patients with inactive PDR; (e) there were significant
correlations between the number of blood vessels expressing
the panendothelial marker CD34 and the number of blood
vessels expressing SCF, G-CSF, eNOS, and CXCR4 and the
number of stromal cells expressing SCF. These data support
the  notion  that  bone  marrow-derived  cells  contribute  to
neovascularization  in  PDR  epiretinal  membranes  and  that
SCF/c-kit signaling may play a role in the pathogenesis of
PDR.
Several studies have demonstrated that c-kit is expressed
by bone marrow-derived progenitor cells that can give rise to
endothelial cells [4,5]. Furthermore, bone marrow-derived c-
kit-positive  cells,  but  not  c-kit-negative  cells,  have  been
reported to produce high levels of vascular endothelial growth
factor (VEGF), differentiate into endothelial cells, and are
incorporated into microvessels of the ischemic hindlimbs of
mice  [4].  Dentelli  et  al.  [6]  showed  that  activated
microvascular  endothelial  cells  challenged  with
interleukin-1β  and  tumor  necrosis  factor  (TNF)-α  express
membrane-bound  SCF  and  that  recruitment  of  circulating
Figure 3. Immunohistochemical staining for CXCR4. Immunoreactivity for CXCR4 was observed in vascular endothelial cells (A: original
magnification 100×) and stromal cells (B: original magnification 40×). Double immunohistochemistry for CXCR4 (red) and c-kit (blue). Cells
co-expressing CXCR4 and c-kit were observed in the vascular endothelium (arrows) and in close association with blood vessels (arrowheads).
C: original magnification 100×.
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1102EPCs  depends  on  c-kit/membrane-bound  SCF  interaction.
Moreover, in an in vivo model of angiogenesis, Dentelli et al.
[6] demonstrated that c-kit /membrane-bound SCF interaction
contributes to EPC recruitment to neovessels. Several studies
have identified SCF/c-kit signaling as an important pathway
involved in neovascularization. SCF/c-kit signaling promoted
the  survival,  differentiation,  migration,  and  capillary  tube
formation of endothelial cells [7,17] and induced new vessel
formation in vivo [17]. Our findings confirm a previous study
showing increased numbers of circulating mononuclear cells
expressing c-kit in patients with diabetic retinopathy [18]. In
addition, another study reported increased circulating EPCs
expressing CD34/CD133 in patients with diabetic retinopathy
[19]. Taken together, these findings suggest that circulating
EPCs are involved in the progression of diabetic retinopathy.
Several  studies  have  demonstrated  that  chronic,  low-
grade  subclinical  inflammation  is  implicated  in  the
pathogenesis of diabetic retinopathy [20] and that leukocytes,
in  particular  macrophages,  are  present  in  diabetic
fibrovascular epiretinal membranes [21-23]. In a previous
study, we demonstrated that the number of leukocytes in PDR
membranes correlated significantly with the number of blood
vessels expressing CD34, VEGF, and angiopoietin-2 and that
the number of leukocytes in PDR membranes from patients
with  active  PDR  was  significantly  higher  than  that  in
membranes from patients with inactive PDR [21]. In addition,
strong evidence indicates that macrophages play a critical role
in the angiogenic process in the retina and choroid by secreting
pro-inflammatory cytokines, such as interleukin-1β and TNF-
α,  that  may  affect  endothelial  cell  functions,  including
proliferation,  migration,  and  activation  [24-26].  These
findings suggest that bone marrow-derived cells could also
indirectly contribute to neovascularization in PDR epiretinal
membranes.
In the present study, we demonstrated the expression of
SCF and c-kit by vascular endothelial cells and stromal cells
in PDR membranes. The expression of both SCF and c-kit by
vascular endothelial cells suggests an autocrine signaling in
the propagation of neovascularization. Our observations are
consistent with previous reports showing upregulation of SCF
in ischemic tissues [2,10] by vascular endothelial cells [2].
The upregulation of SCF was coincident with infiltration of
bone  marrow-derived  c-kit+  cells  [2].  Bosch-Marce  et  al.
[10] showed that the transcription factor hypoxia-inducible
factor-1α is involved in ischemia-induced SCF upregulation.
In a previous study, we demonstrated that vascular endothelial
cells  in  PDR  membranes  expressed  hypoxia-inducible
factor-1α [21]. Our present study supported a previous study
showing that ischemia-induced new vessels in the mesentery
of  diabetic  rats  expressed  c-kit  [9].  In  addition,  c-kit  is
expressed  by  newly  formed  vessels  in  ischemic  limbs  of
patients treated with bone marrow-derived mononuclear cell
therapy [8].
The cytokine G-CSF activates in vitro endothelial cell
proliferation and shows angiogenic activity in vivo [27]. In
addition,  several  studies  have  demonstrated  that  G-CSF
recruits bone marrow-derived c-kit+ EPCs, which differentiate
into endothelial cells, incorporate into the endothelium in
vivo, and enhance neovascularization of ischemic tissue [11,
28]. The neovascularization-promoting effect of G-CSF is
also  mediated  by  augmented  VEGF  secretion  from
neutrophils [11]. In the present study, vascular endothelial
cells in PDR membranes expressed both SCF and G-CSF.
Toth et al. [29] demonstrated that the combination of SCF/G-
CSF has a synergistic effect on the promotion of chemotaxis
of bone marrow-derived endothelial precursors and induction
of bone marrow-derived neovascularization.
In  the  present  study,  c-kit+  cells  in  the  vascular
endothelium and in the stroma co-expressed the chemokine
TABLE 2. MEAN NUMBERS OF BLOOD VESSELS AND CELLS EXPRESSING VARIOUS MARKERS IN RELATION TO THE TYPE OF
PROLIFERATIVE DIABETIC RETINOPATHY (PDR)
Variable Active PDR (n=8;
Mean±S.D.)
Inactive PDR (n=12;
Mean±S.D.)
p-value (Mann–
Whitney test)
Blood vessels expressing CD34 42.6±17.7 18.9±8.0 0.005*
Blood vessels expressing c-kit 13.1±6.9 6.4±5.3 0.03*
Cells expressing c-kit 42.1±43.8 12.9±13.6 0.013*
Blood vessels expressing SCF 7.8±7.1 3.3±3.3 0.128
Cells expressing SCF 20.4±5.0 5.8±6.2 <0.001*
Blood vessels expressing G-CSF 16.8± 8.6 6.1±3.8 0.007*
Blood vessels expressing eNOS 30.6±7.6 16.2±7.4 0.001*
Cells expressing eNOS 40.0±29.1 20.0±10.4 0.048*
Blood vessels expressing CXCR4 29.9±13.2 15.4±8.4 0.018*
Cells expressing CXCR4 107.5±36.5 44.7±33.8 0.003*
*Statistically significant at 5% level of significance.
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.receptor CXCR4. CXCR4 is one of the two receptors for the
chemokine  SDF-1  [30].  Recently,  several  studies
demonstrated that the majority of bone marrow and peripheral
blood c-kit+ cells express the chemokine receptor CXCR4 and
that  SDF-1  induces  their  migration  in  vitro  [12,13]  and
enhances venular rolling of c-kit+ cells in vivo [12]. In a
previous  study,  we  demonstrated  that  SDF-1  protein  was
specifically localized in vascular endothelial cells in PDR
membranes  [16].  Dutt  et  al.  [31]  demonstrated  the
cooperativity  between  SCF  and  SDF-1  in  enhancing  the
chemotaxis of hematopoietic progenitor cells expressing both
the CXCR4 and c-kit receptors. In addition, Tan et al. [32]
showed that the combination of progenitor cell mobilization
with  G-CSF  and  enhanced  homing  of  EPCs  by  SDF-1
promotes neovascularization in ischemic tissue. In the present
study,  the  chemokine  receptor  CXCR4  was  expressed  by
vascular endothelial cells in PDR membranes. Kaminski et al.
[12] showed that stimulation with SDF-1 and TNF-α induces
the expression of CXCR4 on the endothelium and that CXCR4
receptor expression participates in the firm adhesion of c-kit+
cells to the endothelium in vivo. They also described that
eNOS is a crucial and specific factor for firm SDF-1/CXCR4-
mediated c-kit+ cell adhesion to the vascular endothelium. In
addition,  other  studies  have  demonstrated  that  eNOS  is
involved  in  SDF-1/CXCR4-mediated  migration  of  EPCs
[13] and that eNOS is also required for neovascularization in
ischemic tissue [14,15]. In the present study, our analysis
indicated  that  the  number  of  stromal  cells  expressing  the
chemokine receptor CXCR4 was higher than the number of
stromal  cells  expressing  c-kit,  SCF,  and  eNOS.  The
chemokine receptor CXCR4, in contrast to most chemokine
receptors,  is  expressed  on  almost  any  cell  type  [33,34].
Consistent with these studies, we showed in a previous study
the  presence  of  cells  co-expressing  CXCR4  and  the
myofibroblast marker α-smooth muscle actin in proliferative
vitreoretinopathy epiretinal membranes [35].
Several  studies  have  demonstrated  that  MMP-9  is
required for the mobilization and recruitment of bone marrow-
derived c-kit+ endothelial progenitors to ischemic tissue and
is essential for ischemia-induced neovascularization. MMP-9
activity is responsible for the cleavage of membrane SCF into
soluble SCF, which is then available to bind its receptor c-kit.
The  resulting  phosphorylation  of  the  c-kit  receptor
corresponds to the mobilization of peripheral EPCs [2,3]. In
a  previous  study,  we  demonstrated  the  presence  of
immunoreactivity  for  MMP-9  in  myofibroblasts  and  in
vascular  endothelial  cells  in  PDR  membranes  [36].  In
addition,  in  situ  zymography  confirmed  the  presence  of
intense gelatinolytic activity in vascular endothelial cells and
in scattered cells in PDR membranes [36]. Taken together,
these  findings  suggest  that  MMP-9  is  available  and  can
promote the release of soluble SCF enhancing the recruitment
of c-kit+ EPCs into PDR membranes.
In conclusion, our data suggest that bone marrow-derived
c-kit+  cells  contribute  to  new  vessel  formation  in  PDR
fibrovascular membranes and that SCF/c-kit signaling might
contribute to pathological neovascularization in PDR. This
pathway may provide a promising molecular target for anti-
angiogenic therapy.
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